SEARCH:   Advanced

Blood, 1 March 2006, Vol. 107, No. 5, pp. 1892-1895. Prepublished online as a Blood First Edition Paper on October 25, 2005; DOI 10.1182/blood-2005-10-4066. This Article Full Text (PDF) Supplemental Figures Erratum (v107,p3454) All Versions of this Article: 2005-10-4066v1 107/5/1892    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Elliott, S. Articles by Begley, C G Search for Related Content PubMed PubMed Citation Articles by Elliott, S. Articles by Begley, C G Related Collections Related Letters in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 12, 2005 Accepted October 13, 2005 Anti-Epo receptor antibodies do not predict Epo receptor expression Steve Elliott*, Leigh Busse, Michael B Bass, Hsieng Lu, Ildiko Sarosi, Angus M Sinclair, Chris Spahr, Moonkyoung Um, Gwyneth Van, and C G Begley Amgen Inc., Thousand Oaks, CA, USA Whitehead Institute for Biomedical Research, Cambridge, MA, USA * Corresponding author; email: selliott{at}amgen.com. Investigators using anti-EpoR antibodies for immunoblotting and immunostaining have reported erythropoietin receptor (EpoR) expression in nonhematopoietic tissues including human tumors. However, these antibodies detected proteins of 66 to 78 kDa, significantly larger than the predicted molecular weight of EpoR (56 to 57 kDa). We investigated the specificity of these antibodies and showed that they all detected non-EpoR proteins. C-20 detected 3 proteins in tumor cell lines (35, 66, and 100 kDa). Sequences obtained from preparative gels had similarity to the C-20-immunizing peptide. The 66-kDa protein was a heat shock protein (HSP70) to which antibody binding was abrogated in peptide competition experiments. Antibody M-20 readily identified a 59-kDa EpoR protein. However, neither M-20 nor C-20 was suitable for detection of EpoR using immunohistochemical methods. We concluded that these antibodies have limited utility for detecting EpoR. Thus, reports of EpoR expression in tumor cells using these antibodies should be viewed with caution. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letters in Blood Online: Selected anti-Epo receptor antibodies predict Epo receptor expression Frédèrique Verdier, Sophie Gomez, Catherine Lacombe, Patrick Mayeux, Steve Elliott, Angus M. Sinclair, and C. Glenn Begley Blood 2006 108: 1106-1107. [Full Text] [PDF] Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate Michael Henke, Ajay Verma, Geza Acs, Steve Elliott, Leigh Busse, Chris Spahr, and Angus M. Sinclair Blood 2006 108: 1107-1109. [Full Text] [PDF] This article has been cited by other articles: B. K. Hadland and G. D. Longmore Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms J. Clin. Oncol., September 1, 2009; 27(25): 4217 - 4226. [Abstract] [Full Text] [PDF] A.-M. Larsson, K. Jirstrom, E. Fredlund, S. Nilsson, L. Ryden, G. Landberg, and S. Pahlman Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer Clin. Cancer Res., September 1, 2009; 15(17): 5552 - 5559. [Abstract] [Full Text] [PDF] M. Aapro and J. L. Spivak Update on Erythropoiesis-Stimulating Agents and Clinical Trials in Oncology Oncologist, September 1, 2009; 14(suppl_1): 6 - 15. [Abstract] [Full Text] [PDF] J. Fandrey and M. Dicato Examining the Involvement of Erythropoiesis-Stimulating Agents in Tumor Proliferation (Erythropoietin Receptors, Receptor Binding, Signal Transduction), Angiogenesis, and Venous Thromboembolic Events Oncologist, September 1, 2009; 14(suppl_1): 34 - 42. [Abstract] [Full Text] [PDF] J. L. Spivak, P. Gascon, and H. Ludwig Anemia Management in Oncology and Hematology Oncologist, September 1, 2009; 14(suppl_1): 43 - 56. [Abstract] [Full Text] [PDF] D. Mihov, J. Vogel, M. Gassmann, and A. Bogdanova Erythropoietin activates nitric oxide synthase in murine erythrocytes Am J Physiol Cell Physiol, August 1, 2009; 297(2): C378 - C388. [Abstract] [Full Text] [PDF] J.-Y. Jeong, G. Hoxhaj, A. L. Socha, A. J. Sytkowski, and L. Feldman An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells Mol. Cancer Res., July 1, 2009; 7(7): 1150 - 1157. [Abstract] [Full Text] [PDF] J. Chen, K. M. Connor, C. M. Aderman, K. L. Willett, O. P. Aspegren, and L. E. H. Smith Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1329 - 1335. [Abstract] [Full Text] [PDF] R. El Hasnaoui-Saadani, A. Pichon, D. Marchant, P. Olivier, T. Launay, P. Quidu, M. Beaudry, A. Duvallet, J.-P. Richalet, and F. Favret Cerebral adaptations to chronic anemia in a model of erythropoietin-deficient mice exposed to hypoxia Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2009; 296(3): R801 - R811. [Abstract] [Full Text] [PDF] A. Inthal, G. Krapf, D. Beck, R. Joas, M. O. Kauer, L. Orel, G. Fuka, G. Mann, and E. R. Panzer-Grumayer Role of the Erythropoietin Receptor in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Clin. Cancer Res., November 15, 2008; 14(22): 7196 - 7204. [Abstract] [Full Text] [PDF] K. M. Kirschner, P. Hagen, C. S. Hussels, M. Ballmaier, H. Scholz, and C. Dame The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells FASEB J, August 1, 2008; 22(8): 2690 - 2701. [Abstract] [Full Text] [PDF] M. O. Arcasoy Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690. [Abstract] [Full Text] [PDF] C. Bose and K. B. Udupa Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals Am J Physiol Cell Physiol, August 1, 2008; 295(2): C394 - C405. [Abstract] [Full Text] [PDF] A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski Erythropoietin and Erythropoietin Receptor in Colorectal Cancer International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276. [Abstract] [PDF] F. Mannello and G. A. M. Tonti Erythropoietin and Its Receptor in Breast Cancer: Putting Together the Pieces of the Puzzle Oncologist, July 1, 2008; 13(7): 761 - 768. [Abstract] [Full Text] [PDF] R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349. [Abstract] [Full Text] [PDF] J. Fandrey Erythropoietin Receptors on Tumor Cells: What Do They Mean? Oncologist, May 1, 2008; 13(suppl_3): 16 - 20. [Abstract] [Full Text] [PDF] D. Yoon, N. Agarwal, and J. T. Prchal Does Erythropoietin Promote Tumor Growth? Clin. Cancer Res., March 15, 2008; 14(6): 1920 - 1920. [Full Text] [PDF] P. Saintigny, B. Besse, J.-C. Soria, J.-F. Bernaudin, and P. Callard Does Erythropoietin Promote Tumor Growth? Clin. Cancer Res., March 15, 2008; 14(6): 1920 - 1921. [Full Text] [PDF] R. E. Smith Jr, M. S. Aapro, H. Ludwig, T. Pinter, M. Smakal, T. E. Ciuleanu, L. Chen, T. Lillie, and J. A. Glaspy Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Oncol., March 1, 2008; 26(7): 1040 - 1050. [Abstract] [Full Text] [PDF] A. G. Shankar The Role of Recombinant Erythropoietin in Childhood Cancer Oncologist, February 1, 2008; 13(2): 157 - 166. [Abstract] [Full Text] [PDF] V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF] E. Bodo, A. Kromminga, W. Funk, M. Laugsch, U. Duske, W. Jelkmann, and R. Paus Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin FASEB J, October 1, 2007; 21(12): 3346 - 3354. [Abstract] [Full Text] [PDF] J. Soliz, C. Soulage, D. M. Hermann, and M. Gassmann Acute and chronic exposure to hypoxia alters ventilatory pattern but not minute ventilation of mice overexpressing erythropoietin Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1702 - R1710. [Abstract] [Full Text] [PDF] K. C. Sizer Heat Shock Protein 70, Erythropoietin, and Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4326 - 4326. [Full Text] [PDF] P. Saintigny, B. Besse, P. Callard, A.-C. Vergnaud, S. Czernichow, M. Colombat, P. Girard, P. Validire, J.-L. Breau, J.-F. Bernaudin, et al. Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non Small Cell Lung Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4825 - 4831. [Abstract] [Full Text] [PDF] T. R. J. Lappin, A. P. Maxwell, and P. G. Johnston In Reply Oncologist, August 1, 2007; 12(8): 1032 - 1034. [Full Text] [PDF] A. J. Sytkowski Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells Sci. Signal., July 17, 2007; 2007(395): pe38 - pe38. [Abstract] [Full Text] [PDF] E. Gao, M. Boucher, J. K. Chuprun, R.-H. Zhou, A. D. Eckhart, and W. J. Koch Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H60 - H68. [Abstract] [Full Text] [PDF] L. Meyer, B. Deau, H. Forejtnikova, D. Dumenil, F. Margottin-Goguet, C. Lacombe, P. Mayeux, and F. Verdier {beta}-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation Blood, June 15, 2007; 109(12): 5215 - 5222. [Abstract] [Full Text] [PDF] F. D. Ragione, V. Cucciolla, A. Borriello, A. Oliva, and S. Perrotta Erythropoietin Receptors on Cancer Cells: A Still Open Question J. Clin. Oncol., May 1, 2007; 25(13): 1812 - 1813. [Full Text] [PDF] N. Agarwal, V. R. Gordeuk, and J. T. Prchal Are Erythropoietin Receptors Expressed in Tumors? Facts and Fiction--More Careful Studies Are Needed J. Clin. Oncol., May 1, 2007; 25(13): 1813 - 1814. [Full Text] [PDF] M. Henke, D. Mattern, and F. Pajonk In Reply J. Clin. Oncol., May 1, 2007; 25(13): 1815 - 1815. [Full Text] [PDF] A. Sturiale, S. Campo, E. Crasci, G. Coppolino, D. Bolignano, G. Grasso, and M. Buemi Erythropoietin and its lost receptor Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1484 - 1485. [Full Text] [PDF] W. Jelkmann and M. Laugsch Problems in Identifying Functional Erythropoietin Receptors in Cancer Tissue J. Clin. Oncol., April 20, 2007; 25(12): 1627 - 1628. [Full Text] [PDF] T. R. Lappin, A. P. Maxwell, and P. G. Johnston Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia Oncologist, April 1, 2007; 12(4): 362 - 365. [Full Text] [PDF] M. Fantacci, P. Bianciardi, A. Caretti, T. R. Coleman, A. Cerami, M. Brines, and M. Samaja Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia PNAS, November 14, 2006; 103(46): 17531 - 17536. [Abstract] [Full Text] [PDF] M. Henke, D. Mattern, M. Pepe, C. Bezay, C. Weissenberger, M. Werner, and F. Pajonk Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings? J. Clin. Oncol., October 10, 2006; 24(29): 4708 - 4713. [Abstract] [Full Text] [PDF] M. Henke, A. Verma, G. Acs, S. Elliott, L. Busse, C. Spahr, and A. M. Sinclair Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate Blood, August 1, 2006; 108(3): 1107 - 1109. [Full Text] [PDF] M. Beullens, J. R. Delanghe, and M. Bollen False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise Blood, June 15, 2006; 107(12): 4711 - 4713. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020